Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta (Yifan Pharma Press Release) - Mar 31, 2021 - "Evive Biotech...today announced the submission of its Biologics License Application (BLA) for Ryzneuta™ (also known as F-627) to the US Food & Drug Administration (FDA). The submission follows the successful conclusion of Evive's Global Phase III Clinical Trials (NCT03252431 and NCT02872103), which met its primary and secondary endpoints, demonstrating strong and lasting benefit for patients...Ryzneuta™ is a novel treatment for chemotherapy-induced neutropenia (CIN)..."
BLA • Neutropenia • Oncology
|
|
"Evive Biotech...today announced the submission of its Biologics License Application (BLA) for Ryzneuta™ (also known as F-627) to the US Food & Drug Administration (FDA). The submission follows the successful conclusion of Evive’s Global Phase III Clinical Trials (NCT03252431 and NCT02872103), which met its primary and secondary endpoints, demonstrating strong and lasting benefit for patients."
|